FUSILEV Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6500829 | ACROTECH BIOPHARMA | Substantially pure diastereoisomers of tetrahydrofolate derivatives |
Mar, 2022
(2 years ago) | |
Fusilev is owned by Acrotech Biopharma.
Fusilev contains Levoleucovorin Calcium.
Fusilev has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Fusilev are:
- US6500829
Fusilev was authorised for market use on 07 March, 2008.
Fusilev is available in powder;intravenous, solution;intravenous dosage forms.
The generics of Fusilev are possible to be released after 07 March, 2022.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-10) | Apr 29, 2018 |
| Orphan Drug Exclusivity(ODE) | Mar 07, 2015 |
| New Indication(I-637) | Apr 29, 2014 |
Drugs and Companies using LEVOLEUCOVORIN CALCIUM ingredient
Market Authorisation Date: 07 March, 2008
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS; POWDER;INTRAVENOUS
How can I launch a generic of FUSILEV before it's drug patent expiration?
More Information on Dosage
FUSILEV family patents
